Here's Why The Best Is Yet to Come for Axsome Therapeutics
The world is very different compared to what it was just a few short weeks ago. Chances are, that's true for your portfolio, too. But investors with a long-term mindset might see no shortage of emerging opportunities.
One stock that's worth a much closer look is Axsome Therapeutics (NASDAQ: AXSM). The development-stage pharma began March with a market valuation of roughly $3 billion, which appeared to be a fairly attractive level considering the company's near-term potential. But the recent volatility has pushed the company's market cap down to about $2 billion.
There are good, company-specific reasons investors have to think twice about the pharma stock in the midst of the unfolding novel coronavirus pandemic. But the best days are still ahead for Axsome Therapeutics.
Source Fool.com
